Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Tango Therapeutics, Inc. TNGX NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
46/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$15.60
-38.4%

Tango Therapeutics, Inc. (TNGX) is a Biotechnology company in the Healthcare sector, currently trading at $25.33. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is TNGX = $16 (-38.4% upside).

Valuation: TNGX trades at a trailing Price-to-Earnings (P/E) of -23.7 (S&P 500 average ~25).

Financials: revenue is $62M, +36.8%/yr average growth. Net income is $102M (loss), growing at +-0%/yr. Net profit margin is -162.9% (negative). Gross margin is 96.3% (+12.5 pp trend).

Balance sheet: total debt is $34M against $346M equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 16.32 (strong liquidity). Debt-to-assets is 8.4%. Total assets: $399M.

Analyst outlook: 10 / 10 analysts rate TNGX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 73/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 62/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).

$15.60
▼ 38.41% Downside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Tango Therapeutics, Inc., the average price target is $15.60, with a high forecast of $19.00, and a low forecast of $12.00.
Highest Price Target
$19.00
Average Price Target
$15.60
Lowest Price Target
$12.00

TNGX SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 73/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 62/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TNGX

✗
VALUE Fail
10/100
TNGX trades at a trailing Price-to-Earnings (P/E) of -23.7 (S&P 500 average ~25). Forward PEG -1.36 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $16, implying -36.8% from the current price $25. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
73/100
TNGX: +36.8%/yr revenue is, +-0%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet TNGX: Debt-to-Equity (D/E) ratio 0.1 (conservative), Current ratio is 16.32 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
62/100
TNGX: Gross margin is 96.3% (+12.5 pp trend), $3B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 62/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 10 / 10 analysts rate TNGX as buy (100%). Analyst consensus target is $16 (-36.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
TNGX: Net profit margin is -162.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.03-22.2
Volume4.37M
Avg Volume (30D)3.29M
Market Cap$2.94B
Beta (1Y)1.32
Share Statistics
EPS (TTM)-0.87
Shares Outstanding$116.17M
IPO Date2020-09-03
Employees155
CEOMalte Peters
Financial Highlights & Ratios
Revenue (TTM)$62.38M
Gross Profit$60.1M
EBITDA$-109.01M
Net Income$-101.59M
Operating Income$-111.29M
Total Cash$343.14M
Total Debt$33.57M
Net Debt$-78.71M
Total Assets$398.69M
Price / Earnings (P/E)-29.1
Price / Sales (P/S)47.17
Analyst Forecast
1Y Price Target$15.00
Target High$19.00
Target Low$12.00
Upside-40.8%
Rating ConsensusBuy
Analysts Covering10
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS87583X1090

Price Chart

Track all markets on TradingView
TNGX
Tango Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
1.03 52WK RANGE 22.20

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$152.54
+3.76%
 KYMR
KYMR
Kymera Therapeutics, Inc.
$89.00
-0.96%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 RLAY
RLAY
Relay Therapeutics, Inc.
$15.49
+5.02%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.54
-0.89%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$30.42
+11.35%
 TYRA
TYRA
Tyra Biosciences, Inc.
$34.97
-0.85%
 NRIX
NRIX
Nurix Therapeutics, Inc.
$16.97
+4.11%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message